Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China

References

• Jennings L, Huang QS, Barr I, Lee PI, Kim W, Buchy P, Sanicas M, Mungall BA, Chen J. Literature review of the epidemiology of influenza B disease in 15 countries in the asia-pacific region. Influenza Other Respir Viruses. 2018;12(3):383–411. doi:10.1111/irv.12522.
   PubMed Web of Science ®Google Scholar
• Vaccines against influenza who position paper - november 2012. Wkly Epidemiol Rec. 2012;87(47):461–76. PMID:23210147.
   PubMedGoogle Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-united states, 2018–19 influenza season. MMWR Recomm Rep. 2018;67(3):1–20. doi:10.15585/mmwr.rr6703a1.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62.
   PubMedGoogle Scholar
• Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, Henriques CM, Njouom R, Fasce RA, Yu H, et al. Epidemiological and virological characteristics of influenza B: results of the global influenza B study. Influenza Other Respir Viruses. 2015;9(Suppl 1):3–12. doi:10.1111/irv.12319.
   PubMedGoogle Scholar
• Orsi A, Colomba GME, Pojero F, Calamusa G, Alicino C, Trucchi C, Canepa P, Ansaldi F, Vitale F, Tramuto F. Trends of influenza b during the 2010–2016 seasons in 2 regions of north and south Italy: the impact of the vaccine mismatch on influenza immunisation strategy. Human Vaccines & Immunotherapeutics. 2018;14(3):523–31. doi:10.1080/21645515.2017.1342907.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ikonen N, Ziegler T. Impact of influenza b lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis. 2014;59(11):1519–24. doi:10.1093/cid/ciu664.
   PubMed Web of Science ®Google Scholar
• Trucchi C, Alicino C, Orsi A, Paganino C, Barberis I, Grammatico F, Canepa P, Rappazzo E, Bruzzone B, Sticchi L, et al. Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in liguria region, Italy. Hum Vaccin Immunother. 2017;13(2):456–63. doi:10.1080/21645515.2017.1264779.
   PubMed Web of Science ®Google Scholar
• Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine vaxigrip tetra: preliminary results in children ≥ 6 months and older adults. Vaccines. 2018;6(1):10. doi:10.3390/vaccines6010014.
   Web of Science ®Google Scholar
• Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, Peng Y, Yang H, Luo J, Zheng J, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010–2012. Influenza Other Respir Viruses. 2014;8(1):53–65. doi:10.1111/irv.12205.
   PubMed Web of Science ®Google Scholar
• Yang J, Atkins KE, Feng L, Pang M, Zheng Y, Liu X, Cowling BJ, Yu H. Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis. Vaccine. 2016;34(47):5724–35. doi:10.1016/j.vaccine.2016.10.013.
   Google Scholar
• Xu L, Qin Y, Yang J, Han W, Lei Y, Feng H, Zhu X, Li Y, Yu H, Feng L, Shi Y. Coverage and factors associated with influenza vaccination among kindergarten children 2–7 years old in a low-income city of north-western China (2014–2016). PLoS One. 2017;12(7):e0181539. doi: 10.1371/journal.pone.0181539.
   Google Scholar
• China CDC. Technical Guidelines for Seasonal Influenza Vaccination in China (2018–2019). 2018 edition.
   Google Scholar
•  Note for Guidance on Harmonisation of Requirements for Influenza Vaccines; 1997 [accessed 1997 March 12]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf
   Google Scholar
• US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry Clinical Data Needed to support the Licensure of Seasonal Inactivated Influenza Vaccines; 2007 [accessed 2007 May 12]. https://www.fda.gov/media/73706/download.
   Google Scholar
• National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). Division of Microbiology and Infectious Diseases (DMID). Pediatric Toxicity Tables, November 2007 draft; 2007 [accessed 2007 November]. https://www.niaid.nih.gov/sites/default/files/dmidpedtox.pdf.
   Google Scholar
• Chinese State Food and Drug Administration (SFDA). Guidelines for grading standard of adverse reactions in clinical trials of preventive vaccines; 2005 [accessed 2005 Oct 14]. http://www.nmpa.gov.cn/WS04/CL2196/322950.html
   Google Scholar
• Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: A phase Ш randomized controlled trial in children. J Infect Dis. 2013;208(4):5440–53. doi:10.1093/infdis/jit263.
   Google Scholar
• Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, et al.  Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012–2013: A randomized, double-blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infect Dis Soc. 2015;4(3):242–51. doi:10.1093/jpids/piu098.
   Google Scholar
• Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6-35 months of age during 2013–2014: Results from a phase II randomized trial. J Pediatric Infect Dis Soc. 2016;5(2):170–9. doi:10.1093/jpids/piv041 http://www.nmpa.gov.cn/WS04/CL2196/322950.html
   Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770–6. doi:10.1016/j.vaccine.2012.11.074.
   Google Scholar
• Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J. 2014; 33(6):630–6. doi:10.1097/inf.0000000000000254.
   Google Scholar
• Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine. 2015; 33(9):1151–9. doi:10.1016/j.vaccine.2015.01.025.
   PubMed Web of Science ®Google Scholar
• Pepin S, Dupuy M, Borja-Tabora CFC, Montellano M, Bravo L, Santos J, de Castro JA, Rivera-Medina DM, Cutland C, Ariza M, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35months: A multi-season randomised placebo-controlled trial in the northern and southern hemispheres. Vaccine. 2019;37(13):1876–84. doi:10.1016/j.vaccine.2018.11.074.
   PubMed Web of Science ®Google Scholar
• Eun BW, Lee TJ, Lee J, Kim KH, Kim DH, Jo DS, Shin SH, Kim H, Kim KH, Kim YK. A randomized, double-blind, active-controlled phase Ш trial of a cell culture-derived quadrivalent inactivated influenza vaccine in healthy south korean children and adolescents 6 months to 18 years of age. Pediatr Infect Dis J. 2019;38(9):e209–e215. doi:10.1097/inf.0000000000002406.
   PubMed Web of Science ®Google Scholar
• Chen Q, Shi JC, Ye Q. Immune Interference of Carrier Proteins in Bacterial Glycoconjugate Vaccines. Chin J Biologicals. 2013;26(7):1034–9. doi:10.13200/j.cjb.2013.07.143.chenq.012 (In Chinese).
   Google Scholar
• Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28(9):2149–56. doi:10.1016/j.vaccine.2009.11.068.
   PubMed Web of Science ®Google Scholar
• Segaloff HE, Leventer-Roberts M, Riesel D, Malosh RE, Feldman BS, Shemer-Avni Y, Key C, Monto AS, Martin ET, Katz MA. Influenza vaccine effectiveness against hospitalization in fully and partially vaccinated children in Israel: 2015–2016, 2016–2017, and 2017-2018. Clin Infect Dis. 2019;69(12):2153–61. doi:10.1093/cid/ciz125.
   PubMed Web of Science ®Google Scholar
• Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, Rivera L, Acosta B, Arroba Basanta ML, Aziz A, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: A multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2(5):338–49. doi:10.1016/s2352-4642(18)30062-2.
   PubMedGoogle Scholar
• Chinese guidelines of Good Clinical Practice (GCP), 2004 edition.
   Google Scholar